Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuke Qianjin is a traditional Chinese medicine available in both tablet and capsule forms, approved by China's National Medical Products Administration. It is primarily used to treat gynecological inflammatory conditions including pelvic inflammatory disease (PID), chronic cervicitis, endometritis, and chronic pelvic inflammatory disease. The medication works by clearing heat and dampness, replenishing qi, and eliminating blood stasis. Clinical studies have shown that Fuke Qianjin has bacteriostatic and anti-inflammatory effects, and when combined with conventional antibiotics, it demonstrates improved clinical efficacy in treating various gynecological conditions. It has been shown to shorten the remission time of clinical symptoms, reduce serum inflammatory factors, improve endometrial thickness, normalize menstruation, and reduce relapse rates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuke Qianjin.